PF-Atlas › Clinical Trials › NCT00106639
A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients
CP-690,550 · Phase 2
Registry ID
NCT00106639
Phase
Phase 2
Status
Completed
Drug / intervention
CP-690,550
Sponsor
Pfizer
Start
2005-05
Enrollment
61
Locations
20
About this trial
This Phase 2 study was designed to evaluate the safety and efficacy of 2 dose levels of CP-690,550 (15 mg twice daily and 30 mg twice) against tacrolimus, in combination with basiliximab induction, mycophenolate mofetil and corticosteroids, in kidney transplant patients. Stage 1 was to randomize approximately 54 subjects. After all Stage 1 subjects had completed 6 months of treatment, Stage 2 was to randomize an additional 195 subjects to the same treatment groups.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT00106639 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.